Menu
Not yet recruiting NCT06863285

Asthma Control Through Telemedicine

No phase Interventional Asthmatic Patients

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Educational.
Who it may be relevant to
Registry conditions: Asthmatic Patients. Basic parameters: from 11 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Pakistan
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

The Pharmacist Led Educational Interventions Through Telemedicine to Improve Asthma Control: a Randomized Control Trial

Overview

The purpose of this research study is to evaluate the impact of pharmacist led educational interventions on Asthmatic patients, and also determine their medication adherence. Pharmacist's intervention aims to answer: 1. How a pharmacist intervention program impact medication adherence in persistent asthma? 2. To assess how pharmacist led educational intervention like patients' counseling and medication reminders through Telemedicine have an impact on patient's asthma control? 3. Which mode of communication (Verbal instructions, videos and pamphlets) for the patient counselling is most beneficial for the patients in asthma control.

Detailed description

This is a randomized, pharmacist-led, two-group, longitudinal descriptive interventional study performed through in person (Public and private hospitals) and telecommunication (WhatsApp, network calls and messaging). The investigator will use snowball method to approach patients through telecommunication. Recruited patients will be randomly divided into two groups: the Control and the experimental group. The Control Group will not receive any intervention, and experimental group will receive special counseling about persistent asthma, it's medications and medical devices, their appropriate use, and side effects. Using Telemedicine as message and call reminders to increase medication adherence and improve their asthmatic condition. The intervention will be conducted for one month on the experimental group according to the recruitment date and time of the patients.

Pre-validated questionnaires will be used for the assessment

1. The adherence to asthma medication questionnaire (AAMQ-13). 2. Asthma Control test TM (ACT).

Interventions

  • Other Educational
    intervention included the usual counselling by pharmacist e.g. Patients Education regarding Medications * Pharmacist counseling patients regarding their disease and severity * Pharmacist counseling (5- to 10-minute sessions) on the proper and safe use of medication. * Pharmacist counseling patients regarding the importance of their therapy (treatment), non-pharmacological treatment like diet and exercises. pharmacist counselling regarding the preventive measures that prevent patient from trigg

Primary outcome measures

  • Asthma Control Score [Time frame: 1 month]
  • Patients Medication Adherence Score [Time frame: 1 month]

Eligibility criteria

Inclusion criteria

  • Age above 11 years.
  • Persistent Asthma Patient.
  • Patients taking medications and inhaler.
  • Patient who will consent for the study.
  • Patient with basic telecommunication facility.
  • Patient who responded to messages and calls.

Exclusion criteria

  • Patients who will refuse to participate in study will not be included.
  • Irresponsive patients to messages and calls

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Supportive care

Study locations

Pakistan · 1 center
  • Hamdard University — Islamabad

Identifiers

NCT: NCT06863285 · ABJan012025

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗